Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data. RAHWAY, N.J., January 31, 2025--Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...

Um programa de sustentabilidade da cacauicultura brasileira, com mais de 6.000 produtores parceiros, pretende atingir a meta de 100% de cacau sustentável em 2025. O projeto ‘Mais Inteligência ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Segundo a organização, co-financiada pela União Europeia, este programa "aumenta a sensibilização, prepara avaliações independentes e propõe recomendações de acção", prevendo uma apoio ...

Rumours that Merck was planning a $30 billion-plus takeover bid for Seagen have so far come to nothing, but it did complete a deal to buy VelosBio for $2.75 billion in late 2020 to add an ADC ...